Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BEAM-103 · 1 trial · 2 indications
Incidence of treatment-emergent AEs, serious AEs, severe AEs, AEs related to BEAM-103
| Arm | Type | Description |
|---|---|---|
| BEAM-103 Drug Product | EXPERIMENTAL | BEAM-103 is a monoclonal antibody that will be administered in single dose ascending dose cohorts as an intravenous infusion through the arm. |
| Placebo | PLACEBO_COMPARATOR | Normal Saline Solution will be administered as a matching place in single dose ascending dose cohorts as an intravenous infusion through the arm. |
| Name | Type | Description |
|---|---|---|
| BEAM-103 | DRUG | • BEAM-103 is a monoclonal antibody administered as a single intravenous dose |
| Placebo Comparator | DRUG | • The matching placebo comparator is administered as a single intravenous dose |
Inclusion Criteria: * Ages 18 to ≤55 years * Body mass index (BMI) of 18.5 to 25 kg/m2 * Morning neutrophil count ≥2.6 × 109 cells/L for Black/African American subjects or ≥3.5 ×109 cells/L for Caucasian/Other subjects * Baseline hemoglobin value of ≥14 g/dL for males and ≥12 g/dL for females * Bas...
BEAM-103 is an investigational small molecule developed by Beam Therapeutics Inc. It is being studied in a Phase 1 clinical trial in healthy adult subjects in the United Kingdom. The study is designed to assess safety, pharmacokinetics, and pharmacodynamics of the drug candidate.
BEAM-103 targets CD117, a protein also known as KIT. CD117 is a receptor tyrosine kinase. By binding this protein target, BEAM-103 is designed to modulate CD117-related signaling, which is the basis for its evaluation in early-stage clinical testing.
BEAM-103 is developed by Beam Therapeutics Inc., a biotechnology company that trades on the Nasdaq under the ticker BEAM. The company is the sponsor of the Phase 1 study evaluating BEAM-103 in healthy volunteers.
BEAM-103 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The ongoing Phase 1 trial is a randomized, single-blind, placebo-controlled study in healthy subjects.
BEAM-103 is being evaluated in one clinical trial, NCT07304791. This Phase 1 study is randomized, single-blind, and placebo-controlled, with an planned enrollment of 30 healthy subjects. It is currently recruiting participants in the United Kingdom and is designed to assess safety, pharmacokinetics, and pharmacodynamics.